Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 1 · 33.3%High 1 · 33.3%

Omega‐3 vs placebo

Serious adverse events: death · Dialysis vascular access outcomes in AVF patients with ESKD

Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (moderate certainty).

1 finding from 1 review

Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only
RD 0
1 study · 567 participants
Moderate

Omega‐3 vs placebo

Serious adverse events: death · dialysis vascular access outcomes in AVG patients with ESKD

Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (low certainty).

1 finding from 1 review

Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes only
RD 0.01
4 studies · 261 participants
Low

Serious adverse events "Defined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (Quinn 2010) · Apathy in people with mild‐to‐moderate Alzheimer's disease

Omega‐3 PUFA supplements showed no clear difference in serious adverse events "Defined as events that result in death,… compared with placebo (high certainty).

1 finding from 1 review

Omega‐3 fatty acids for the treatment of dementia 2016 · Cochrane Headline outcomes only
RR 1.05 [0.78, 1.41]
1 study · 402 participants
High